IRVINE, Calif.--(BUSINESS WIRE)--Cobalis Corp. (OTC BB: CLSC) a pharmaceutical development company specializing in anti-allergy medications, announced today that it has received its Second Closing of $675,000 in accordance with the terms of its Security Purchase Agreement dated December 20, 2006.
